Life Sciences

  • February 6, 2018

    FDA Warning Wire: Zimmer Biomet Zapped Again

    Zimmer Biomet once again found itself in the crosshairs of the U.S. Food and Drug Administration, which also warned two drugmakers in Asia about quality issues such as fiber particles in drug vials.

  • February 6, 2018

    Stericycle To Pay Workers $2M To End Wage, Break Claims

    Stericycle Inc. employees asked a California federal judge on Monday to preliminarily approve a $2 million agreement with the medical waste disposal company settling putative class claims that it denied workers breaks and shorted them on overtime pay and compensation for time spent changing into their work wear.

  • February 6, 2018

    Adocia Adds $200M To Arbitration Demand Against Eli Lilly

    French biopharmaceutical company Adocia SA is seeking over $200 million more in damages from Eli Lilly and Co. in arbitration over an abandoned partnership on the diabetes treatment BioChaperone Lispro, adding claims that Lilly misused Adocia's trade secrets and breached confidentiality agreements.

  • February 6, 2018

    4th Circ. Upholds $18.5M Boston Scientific Mesh Verdict

    The Fourth Circuit on Tuesday rejected Boston Scientific Corp.'s appeal of an $18.5 million verdict in a trial over injuries allegedly caused by its Obtryx pelvic mesh devices, saying the company had gotten a fair trial.

  • February 6, 2018

    Valeant Seeks To Move NY Investor Fraud Suit To NJ

    Valeant Pharmaceuticals International Inc. and others who were sued in Manhattan federal court by three investment funds over alleged fraud and price-gouging have asked the court to send the case to New Jersey, where it would be bundled with dozens of other similar suits.

  • February 6, 2018

    Alabama Sues Purdue Pharma Over Role In Opioid Crisis

    The state of Alabama has hit Purdue Pharma LP with a lawsuit accusing the drugmaker of exacerbating the state’s opioid epidemic by marketing the drugs as safe to treat common chronic pain and downplaying the risk of addiction, Attorney General Steve Marshall said Tuesday.

  • February 5, 2018

    Surgery Center, Estate Contest Punitives In Meningitis MDL

    A Maryland surgery center linked to a deadly meningitis outbreak involving contaminated epidural painkillers exchanged salvos Friday with the estate of a deceased patient in Massachusetts federal court multidistrict litigation over whether the estate was entitled to punitive damages under either of those states’ laws.

  • February 5, 2018

    Ex-Doc Gets 8 Years For Fraud, Illegally Dispensing Opioids

    A former Kentucky doctor will serve eight years in prison after pleading guilty to nearly 50 charges of illegal distribution of opioids and health care fraud, the U.S. Department of Justice said Monday.

  • February 5, 2018

    Bayer Offers Commitments To EU For $63.5B Monsanto Buy

    German drug and chemical maker Bayer AG on Friday sent Europe's antitrust enforcers a new set of commitments aimed at curing competitive concerns raised by its planned $63.5 billion buyout of U.S. agrochemical company Monsanto Co.

  • February 5, 2018

    Cornell University Can't Restart Settled Patent Fight

    A Delaware federal magistrate judge Monday told Cornell University that the federal courts can’t restart a settled patent case over allegations it was defrauded by its own co-plaintiff.

  • February 5, 2018

    Ex-Aveo Exec Fights SEC Penalty, Says He's Learned Lesson

    A former Aveo Pharmaceuticals Inc. executive continued to argue in Massachusetts federal court Monday that he should not have to pay a fine or be barred from leadership positions over the Securities and Exchange Commission’s allegations that he deceived investors about Aveo's flagship kidney cancer drug, saying he had learned his lesson.

  • February 5, 2018

    Fed. Circ. Backs Toss Of AbbVie's Humira License Suit

    The Federal Circuit on Monday affirmed the dismissal of a declaratory judgment suit AbbVie filed seeking to invalidate a patent it licensed from MedImmune for use in the blockbuster drug Humira, ruling the suit can’t proceed because it wouldn’t resolve the companies’ license dispute.

  • February 5, 2018

    Deals Rumor Mill: Pfizer, ADM, Bhushan Steel

    Pfizer's consumer health unit reportedly only received bids by GlaxoSmithKline and Reckitt Benckiser Group, food processing giant Archer Daniels Midland is in talks to swallow rival commodities trader Bunge as soon as this week, and Bhushan Steel has received two bids for its business.

  • February 5, 2018

    US Teva Worker Can Sue Co.'s Israeli Branch, Judge Says

    A Pennsylvania federal judge on Monday declined to free the Israeli branch of Teva Pharmaceuticals USA Inc. from an age discrimination suit brought by a senior facilities manager in the United States on grounds that the unit had significant control over American business operations.

  • February 5, 2018

    Vertex To Pay $4.75M To End TCPA Case Over Hep C Faxes

    A Massachusetts federal judge was asked Friday to preliminarily approve Vertex Pharmaceuticals Inc.’s $4.75 million settlement to end putative class action claims the company violated the Telephone Consumer Protection Act by faxing unsolicited invitations to an event about its hepatitis C therapy.

  • February 5, 2018

    Atty Scolded For '#Killinnazis' Exits Pa. Xarelto Cases

    A Florida attorney who was chided by a Philadelphia judge last month for posting courtroom photos on social media with the inflammatory hashtag “#killinnazis" will not be involved in six upcoming trials over injuries allegedly caused by Bayer AG’s blood thinner Xarelto, according to an order docketed Friday.

  • February 5, 2018

    IRS Asks Supreme Court To Skip Appeal In Marijuana Case

    The IRS on Friday defended its authority to deny tax credits to drug traffickers and urged the U.S. Supreme Court to deny an appeal by a Colorado marijuana company that argued the IRS lacks the power to investigate drug cases.

  • February 2, 2018

    Amgen's Suit To Shield Cancer Treatment Biosimilar Tossed

    A California federal judge on Friday granted a motion by Genentech to toss a complaint brought by Amgen seeking to invalidate more than two dozen patents related to Genentech’s cancer treatment Avastin, finding that Amgen was bypassing a negotiation scheme required by law.

  • February 2, 2018

    Biomed Co. Appealed Too Late In Trade Secrets Row: 7th Circ.

    German bone cement manufacturer Heraeus Kulzer GmbH was dealt a blow by the Seventh Circuit on Thursday, which ruled the company had not appealed in a timely fashion in relation to a trade secrets dispute with competitor Biomet Inc. 

  • February 2, 2018

    10 Firms To Steer IPOs Exceeding $1.8B To Start February

    Ten firms are guiding 10 companies scheduled to price 10 initial public offerings exceeding $1.8 billion during the week of Feb. 5, led by two energy services companies, marking a busy start to the month after a record-breaking January.

Expert Analysis

  • Top 4 Health Care Cybersecurity Threats For 2018

    Brad Sayles

    2017 introduced some of the largest and most widespread cybersecurity attacks in recent memory, and the health care industry was shown to be particularly vulnerable. Brad Sayles of Nelson Mullins Riley & Scarborough LLP discusses the most significant risks health care providers should be on the watch for this year.

  • The Broader Implications Of Sessions’ Marijuana Move

    Markus Funk

    Beyond what it heralds for the marijuana industry, Jeff Sessions’ memo on marijuana enforcement signals a new era of increasingly decentralized federal prosecutorial power, say attorneys with Perkins Coie LLP, including former Colorado Chief Justice Michael Bender.

  • Litigation Finance Trends To Watch In 2018

    Jay Greenberg

    Jay Greenberg and Max Volsky, co-founders of litigation finance platform LexShares Inc., analyze emerging trends based on conversations with their investors and executives in this rapidly evolving sector.

  • 5 Health Care Policy Issues To Follow In 2018

    Pari Mody

    As the 115th Congress enters its second session, it's expected that health care policy will remain at the forefront. Pari Mody and Kristine Blackwood of Arnold & Porter Kaye Scholer LLP discuss the top five health care policy issues to track this year.

  • Why Sales Rep Witness Tampering Accusations Matter

    Ryan O'Neil

    In two recent product liability trials, plaintiffs have alleged that witnesses were improperly contacted by pharmaceutical and medical device sales representatives. Such allegations can be damaging to a case and to attorney credibility, and can divert precious resources midtrial, while sidelining the actual products liability claims at issue, say Ryan O’Neil and Anne Gruner of Duane Morris LLP.

  • The Enneagram And The Practice Of Law

    Jennifer Gibbs

    Study of the Enneagram personality typing system can provide attorneys with better insights into themselves, and into those they interact with professionally, including clients, opposing counsel and judges, says Jennifer Gibbs of Zelle LLP.

  • Massachusetts Marijuana Regulatory Scheme Takes Shape

    Robert Munnelly Jr.

    Massachusetts' emerging regulatory program for both recreational and medical use marijuana, supervised by its new Cannabis Control Commission, will serve as a national model for cannabis industry players and regulators, say Robert Munnelly Jr. and Shawn McCormack of Davis Malm & D'Agostine PC.

  • Series

    Judging A Book: Tymkovich Reviews 'Gorsuch'

    Timothy Tymkovich

    John Greenya’s new book, “Gorsuch: The Judge Who Speaks for Himself,” offers readers something the confirmation hearings did not — the backstory of Neil Gorsuch and a glimpse of who Justice Gorsuch is, says Chief Judge Timothy Tymkovich of the Tenth Circuit.

  • The Hottest Patent Law Issues Of 2017

    Lawrence E. Ashery

    As we start the new year, Lawrence E. Ashery of Caesar Rivise PC looks back at the 12 most important patent law opinions of 2017.

  • 5 Things To Watch For In FCPA Enforcement This Year

    David Simon

    After much hand-wringing in 2017 about whether Foreign Corrupt Practices Act enforcement would diminish radically under President Donald Trump, it’s now safe to say that all signs point toward continued and vigorous enforcement, say attorneys with Foley & Lardner LLP.